our Premium Content: News alerts, weekly reports and conference planners

GENE:

PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)

News alerts, weekly reports and conference planners

15d

Glyphosate-Induced Metabolic and Immune Modulation in Hepatoma Cells: Identification of Key Genes as Diagnostic and Therapeutic Targets Using an In Silico Systems Biology Approach. (PubMed, J Xenobiot)

Notably, all hub genes demonstrated strong diagnostic performance, highlighting their potential as sensitive biomarkers of glyphosate exposure. Collectively, this study provides comprehensive insights into gene expression changes associated with glyphosate exposure in hepatoma cells, linking them to hepatic metabolic dysregulation and immune modulation and suggesting a panel of hub genes with potential diagnostic and therapeutic significance.

15 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • CD36 (thrombospondin receptor) • ALDOA (Aldolase Fructose-Bisphosphate A) • ATF3 (Activating Transcription Factor 3) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) • PGK1 (Phosphoglycerate Kinase 1) • PNPLA3 (Patatin Like Phospholipase Domain Containing 3) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)

Integrated RNA-seq and RT-qPCR Workflow Identifies Non-IGH Fusion Transcripts as Individualized Molecular Markers for Monitoring Multiple Myeloma. (PubMed, Biomedicines)

These findings suggest that individualized fusion transcripts serve as robust molecular markers for MRD surveillance. The proposed RNA-seq-RT-qPCR pipeline offers a clinically practical strategy to enhance precision diagnosis and personalized treatment in MM.

1 month ago

Journal

IGH (Immunoglobulin Heavy Locus) • DDX5 (DEAD-Box Helicase 5) • EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)

Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer. (PubMed, Res Sq)

Conclusions CDK4/6 inhibition rewires glucose metabolism in ER + breast cancer by increasing glycolytic flux while limiting downstream glucose utilization, resulting in heightened reliance on regulated glycolytic control to maintain metabolic homeostasis during cell cycle arrest. Disruption of this adaptive metabolic state through PFKFB3 inhibition enhances the antitumor effects of CDK4/6 inhibition and supports the therapeutic potential of targeting glycolytic regulation in combination with CDK4/6 inhibitor-directed therapies.

1 month ago

Journal

ER (Estrogen receptor) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)

ER positive

2ms

Targeting PFKFB3-dependent endothelial-mesenchymal transition by luteolin attenuates doxorubicin-induced cardiotoxicity. (PubMed, Phytomedicine)

These findings indicated that luteolin ameliorated DIC by targeting PFKFB3 to inhibit EndMT. Luteolin may be a promising adjuvant therapy for mitigating DIC.

2 months ago

Journal

PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)

doxorubicin hydrochloride

2ms

Hypoxia-induced circ_0017521 enhances glycolysis and promotes NSCLC progression via upregulating the PFKFB3/PI3K-AKT pathway. (PubMed, Mamm Genome)

RNase R digestion and actinomycin D assays were employed to assess its stability...Animal experiments confirmed that silencing circ_0017521 suppressed tumor growth and glycolysis. This study revealed that hypoxia-induced circ_0017521 activated the PI3K/AKT pathway through the miR-532-3p/PFKFB3 axis, synergistically driving EMT and glycolysis, thereby promoting NSCLC progression.

2 months ago

Journal

LDHA (Lactate dehydrogenase A) • MIR532 (MicroRNA 532) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) • SLC2A1 (Solute Carrier Family 2 Member 1)

dactinomycin

2ms

ADARB1 inhibits glycolysis and progression of cervical cancer through the HMGB1/PFKFB3 axis. (PubMed, Biochim Biophys Acta Mol Basis Dis)

ADARB1 exerts its anti-tumor effects primarily through the HMGB1/PFKFB3 pathway. Collectively, these findings identify ADARB1 as a novel tumor suppressor in cervical cancer and a promising therapeutic target for clinical intervention.

2 months ago

Journal

HMGB1 (High Mobility Group Box 1) • ADAR (Adenosine Deaminase RNA Specific) • ADARB1 (Adenosine Deaminase RNA Specific B1) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)

2ms

Protein kinase D: Integrating cancer and metabolic disorders. (PubMed, Mol Aspects Med)

These findings highlight PKD isoforms as potential therapeutic targets, particularly in cancer settings where metabolic dysfunction plays a contributing role. While current PKD inhibitors lack isoform specificity, future therapeutic strategies focused on PKD2 and PKD3 modulation may offer selective control over invasion, immune evasion, and metabolic reprogramming in metabolically comorbid cancer patients.

2 months ago

Review • Journal

PD-L1 (Programmed death ligand 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • PKD1 (Polycystin 1) • LEP (Leptin) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) • PKD3 (Polycystic Kidney Disease 3) • PRKD1 (Protein Kinase D1)

3ms

Daucosterol Targets PFKFB3 to Mitigates Sepsis-Induced Acute Lung Injury by Inhibiting Glycolysis and M1 Macrophage Polarization. (PubMed, Chem Biol Drug Des)

In vivo, Daucosterol significantly alleviated CLP-induced ALI by improving lung histopathology, reducing pulmonary edema, enhancing oxygenation, inhibiting myeloperoxidase and caspase-3 activity, and decreasing TNF-α and IL-6 levels in bronchoalveolar lavage fluid. In conclusion, Daucosterol targets PFKFB3 to mitigate sepsis-induced ALI by inhibiting glycolysis and M1 macrophage polarization, offering a potential therapeutic strategy for ALI.

3 months ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • MPO (Myeloperoxidase) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)

3ms

NAT10 promotes the glycolysis of retinoblastoma through ac4C modification of PFKFB3 mRNA. (PubMed, BMC Cancer)

In vivo, NAT10 promoted tumor growth. Collectively, NAT10 contributes to RB progression by enhancing glycolysis through ac4C-mediated PFKFB3 mRNA stabilization, identifying the NAT10-ac4C-PFKFB3 axis as a potential therapeutic target.

3 months ago

Journal

PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)

3ms

Metabolic alterations driven by PFKFB3 upregulation confer resistance to trastuzumab in HER2-positive breast cancer. (PubMed, Biomed Pharmacother)

PFKFB3 upregulation drives metabolic adaptations that confer resistance to trastuzumab in HER2 + breast cancer. These findings highlight PFKFB3 as a promising therapeutic target to overcome resistance and improve patient outcomes.

3 months ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)

HER-2 positive

Herceptin (trastuzumab)

3ms

Inhibition of PFKFB3 in Macrophages Has a Dual Effect on Tumor-Regulating Lipid Metabolism. (PubMed, Int J Mol Sci)

PFKFB3 activity was associated with a specific reduction in asparagine availability, potentially pointing to a targeted reprogramming of amino acid metabolism supporting distinct TAM functions under conditions of intra-tumoral metabolic stress. These findings highlight PFKFB3 as an essential regulator of TAMs pro-tumoral metabolism in CRC, particularly in colon cancer.

3 months ago

Journal

PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3)